Latest / Breastcancer.org Podcast

Top Metastatic Breast Cancer Research at ASCO 2019
Dr. Maura Dickler, vice president of oncology late phase development for Eli Lilly and Company, offers insights on some of the most interesting research on metastatic breast cancer presented at the 2019 American Society of Clinical Oncology Annual Meeting.
Listen to the podcast to hear Dr. Dickler explain:
results from the IMpassion 130 trial looking at Tecentriq (chemical name: atezolizumab) and Abraxane (chemical name: albumin-bound or nab-paclitaxel) to treat metastatic triple-negative breast cancer
results from the Young-PEARL trial studying Ibrance (chemical name: palbociclib) and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.